Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis

Isolation and gene expression of haematopoietic-cell-free preparations of highly purified murine osteocytes

(2015) Ling Yeong Chia et al.   BONE

Short-term and long-term effects of osteoporosis therapies

(2015) Ian R. Reid   Nature Reviews Endocrinology

Future directions for new medical entities in osteoporosis

(2014) Serge Ferrari   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Inhibition of Cathepsin K Increases Modeling-Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys

(2014) Brenda L Pennypacker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib Treatment Affects Trabecular and Cortical Bone in the Femur of Postmenopausal Women: Results of a Two-Year Placebo-Controlled Trial

(2014) Klaus Engelke et al.   JOURNAL OF BONE AND MINERAL RESEARCH

PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis

(2014) Hui Xie et al.   NATURE MEDICINE

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

(2014) H. G. Bone et al.   OSTEOPOROSIS INTERNATIONAL

Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits

(2013) Brenda L Pennypacker et al.   BMC MUSCULOSKELETAL DISORDERS

Steering the osteoclast through the demineralization–collagenolysis balance

(2013) Kent Søe et al.   BONE

Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: A head-to-head comparison with alendronate

(2013) Donald S. Williams et al.   BONE

High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate

(2013) Antonio Cabal et al.   BONE

Vitamin D Status and Bone Mineral Density Changes During Alendronate Treatment in Postmenopausal Osteoporosis

(2013) Christian Roux et al.   CALCIFIED TISSUE INTERNATIONAL

Osteoclast-Derived Coupling Factors in Bone Remodeling

(2013) Kim Henriksen et al.   CALCIFIED TISSUE INTERNATIONAL

Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration

(2013) S. Aubrey Stoch et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats

(2013) Yasuo Ochi et al.   JOURNAL OF BONE AND MINERAL METABOLISM

The Effect of the Cathepsin K Inhibitor ONO-5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study

(2013) Klaus Engelke et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of ONO-5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2-Year Results From the OCEAN Study

(2013) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial

(2013) Sydney Bonnick et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial

(2013) Kim Brixen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

(2013) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Odanacatib, a Selective Cathepsin K Inhibitor, Demonstrates Comparable Pharmacodynamics and Pharmacokinetics in Older Men and Postmenopausal Women

(2013) Matt S. Anderson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study

(2013) T. Nakamura et al.   OSTEOPOROSIS INTERNATIONAL

Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women

(2012) Shinichi Nagase et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers

(2012) S. Aubrey Stoch et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Odanacatib on Bone Mineralization Density Distribution in Thoracic Spine and Femora of Ovariectomized Adult Rhesus Monkeys: A Quantitative Backscattered Electron Imaging Study

(2012) Nadja Fratzl-Zelman et al.   CALCIFIED TISSUE INTERNATIONAL

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

(2012) Bente Langdahl et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation

(2012) Hai Qing et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism

(2011) Yasuo Ochi et al.   BONE

The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking

(2011) P. Leung et al.   BONE

Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway

(2011) K. Kassahun et al.   DRUG METABOLISM AND DISPOSITION

Association of hip strength estimates by finite-element analysis with fractures in women and men

(2011) Shreyasee Amin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

(2011) Patricia J Masarachia et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

(2011) Tara Cusick et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib

(2011) Thomas M. Rnger et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011

(2011) Yang Xue et al.   Orphanet Journal of Rare Diseases

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

(2011) C. Jerome et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits

(2010) Brenda L Pennypacker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteoporosis: impact on health and economics

(2010) Nicholas Harvey et al.   Nature Reviews Rheumatology

Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys

(2009) G. B. Stroup et al.   CALCIFIED TISSUE INTERNATIONAL

Cathepsin K inhibitors for osteoporosis and potential off-target effects

(2009) Dieter Brömme et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

(2008) Jacques Yves Gauthier et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Bone density, strength, and formation in adult cathepsin K (−/−) mice

(2008) B. Pennypacker et al.   BONE

Mechanisms of the Anabolic Effects of Teriparatide on Bone: Insight From the Treatment of a Patient With Pycnodysostosis

(2008) Pascale Chavassieux et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment

(2008) Barbara M Obermayer-Pietsch et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

(2007) Karen Fuller et al.   BONE